Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Duloxetine 60 mg Once Daily Versus Placebo in Patients With Chronic Low Back Pain. [Efecto de Duloxetina 60 mg, Administrado una Vez al Dia, Frente a Placebo, en Pacientes con Lumbalgia Cronica]

Trial Profile

Effect of Duloxetine 60 mg Once Daily Versus Placebo in Patients With Chronic Low Back Pain. [Efecto de Duloxetina 60 mg, Administrado una Vez al Dia, Frente a Placebo, en Pacientes con Lumbalgia Cronica]

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Duloxetine (Primary)
  • Indications Back pain
  • Focus Registrational; Therapeutic Use
  • Acronyms HMGC
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 14 May 2010 Results published in the Journal of Pain.
    • 06 May 2010 Results presented at 29th Annual Scientific Meeting of the American Pain Society.
    • 04 Feb 2010 Actual number of patients changed from 395 to 401 according to Eli Lilly media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top